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Abstract: Emerging laboratory and clinical investigations demonstrate that Hedgehog 
signaling (Hh) represents a novel therapeutic target in various human cancers. This conserved 
signaling pathway precisely regulates self-renewal and terminal differentiation in embryonic 
development, but is typically silenced in adult tissues, with reactivation usually only during tissue 
repair. Aberrant Hh pathway signaling has been implicated in the pathogenesis, self-renewal, 
and chemotherapy resistance of a growing number of solid and hematologic malignancies. 
Major components of the Hh pathway include the Hh ligands (Sonic, Desert, and Indian), the 
transmembrane receptor Patched, the signal transducer Smoothened (Smo), and transcription 
factors Gli1–3 which regulate the transcription of Hh target genes. Mutations in Hh pathway genes, 
increased Hh signaling in tumor stroma, and Hh overexpression in self-renewing cells (cancer 
stem cells) have been described, and these different modes of Hh signaling have implications for 
the design of Hh pathway inhibitors and their integration into conventional treatment regimens. 
Discovery of a naturally-occurring Smo inhibitor, cyclopamine, and the identification of Hh 
pathway mutations and over expression in cancer cells prompted the development of several 
cyclopamine derivatives. Encouraging laboratory and in vivo data has resulted in Phase I and 
II clinical trials of Smo inhibitors. In this review, we will discuss the current understanding of 
Hh pathway signaling in malignancy and Smo antagonists in development. Recent data with 
these agents shows that they are well-tolerated and may be effective for subsets of patients. 
Challenges remain for appropriate patient selection and the optimal combination and sequence 
of these targeted therapies into current treatment paradigms.
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Introduction
A growing body of evidence demonstrates a role for conserved embryonic signaling 
pathways such as Hedgehog (Hh), Wingless, and Notch in the development of human 
cancers.1,2 Preclinical data in various tumor types suggests a role for Hh signaling in 
cancers of the skin,3,4 brain,5,6 lung,7 breast,8 prostate,9,10 colon,11 as well as hematologic 
malignancies including leukemia,12–15 lymphoma,16–19 and multiple myeloma (MM).16,20 
Laboratory data suggests that Hh signaling regulates multiple pathogenic processes 
including tumor growth, self-renewal, and resistance to chemotherapy. Given that Hh 
signaling is implicated in a wide range of malignancies, there is much interest in the 
development of Hh pathway inhibitors as novel anticancer therapy. In this review, we 
will discuss the Hh pathway in cancer, mechanisms of its aberrant activation in differ-
ent tumor types, and its role in the self-renewing cell population, or cancer stem cells 
(CSCs). We will then review published and preliminary data regarding Hh pathway 
inhibitors clinical trials.
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The Hh pathway
The Hh signaling pathway regulates cell differentiation 
and self-renewal in the developing embryo and is typically 
silenced in adult tissues.21 Aberrant Hh signaling may result 
from mutations in pathway genes or overexpression of sig-
naling through other mechanisms in either tumor cells them-
selves or cells in the supportive tumor microenvironment.22–26 
Much of our knowledge of the Hh pathway comes from stud-
ies in Drosophila, and although several major components of 
the pathway are well described, some details remain poorly 
understood. In mammals, one of three Hh pathway ligands 
(Desert, Indian, and Sonic) binds to the transmembrane 
receptor Patched (Ptch) to initiate pathway signaling. In the 
inactive state, Ptch exerts an inhibitory effect on the signal 
transducer Smoothened (Smo), and no downstream signal-
ing occurs. When Hh ligand binds to Ptch, the inhibition on 
Smo is released and downstream signaling occurs, regulating 
the expression of the transcription factors Gli1–3 (Figure 1). 
Primary cilia present on most cells during interphase are 
involved in signal transduction, and Hh pathway components 
translocate during activation. In the inactive state, when Hh 
ligand is not present, Ptch is located in the primary cilia but 
Smo is not. When ligand binds and Ptch inhibition of Smo is 
released, Ptch moves out of the primary cilia and Smo moves 
in to facilitate interaction with Glis and associated proteins. 
They subsequently enter the nucleus and regulate expression 
of Hh target genes.27–32
Hh expression is precisely regulated through both   positive 
and negative feedback loops which may be interrupted by 
mutations in Hh pathway genes themselves or epigenetic 
changes. Increased transcription of Hh target genes results in 
increased cell proliferation and survival, induction of stem cell 
markers, as well as promotion of bone metastases.33   Aberrant 
Hh signaling has also been associated with chemotherapy-
resistance in gliomas,34 pancreatic cancer,35 leukemia,36,37 
lymphoma,17,38 and MM.39 Interactions with other signaling 
pathways, including Notch, PI3K, RAS-MEK/AKT, and 
NF-κB, to promote cancer growth, recurrence, and chemo-
therapy resistance have also been described.40–43
Several Smo inhibitors are in clinical development for 
the treatment of human cancers. Recently, emerging clini-
cal data have demonstrated the potential activity of these 
agents in several diseases, particularly medulloblastoma, 
basal cell carcinoma (BCC), pancreatic cancer, and hemato-
logic malignancies. Ongoing trials will evaluate the role for 
Smo inhibitors as single agents, as well as in combination 
with traditional chemotherapy. This review will discuss the 
mechanisms of Hh signaling in malignancy and the evidence 
for Hh signaling in CSCs. These preclinical studies provide 
the rationale for human trials of Hh inhibition in various 
malignancies, and we will review the progress and challenges 
of translating the laboratory investigations of Smo inhibitors 
into meaningful clinical results for patients.
The Hh pathway in cancer
Similar to its role in normal development, dysregulated Hh 
signaling results in the expression of a number of genes 
responsible for cell proliferation, survival, and self-renewal. 
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Figure 1 Hh signaling pathway. In the absence of Hh ligand, Ptch exerts an inhibitory effect on Smo, and no downstream signaling occurs. In the presence of Hh ligand 
binding to Ptch, the suppression of Smo is released. Smo interacts with Suppressor of fused (SUFU), which promotes the activation and nuclear translocation of Gli1.   
Gli1 translocation results in the transcription of Hh target genes.
Abbreviations: Hh, Hedgehog; Ptch, Patched; Smo, Smoothened, COS, Ccoastal-2; FU, Fused.
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Aberrant Hh signaling is associated with the development 
of cancer, as demonstrated by the Gorlin syndrome, caused 
by an autosomal dominant germline mutation in the 
PTCH1 gene.4,44 This resultant mutated Ptch is unable to 
exert its tonic inhibition of Smo, resulting in hyperactiva-
tion of the pathway. Patients with Gorlin syndrome are 
predisposed to various malignancies, most commonly BCC 
and medulloblastoma.45 These observations led to the dis-
covery of Hh activation in the majority of the more common 
sporadic form of BCC, with mutations in the PTCH1 allele 
occurring in up to 30% of cases3 and SMO mutations in 
approximately 10%.46 In addition, mutations in Hh pathway 
genes have been implicated in the pathogenesis of up to 30% 
of sporadic medulloblastoma.47
Mechanisms of Hh signaling in cancer
Although Hh pathway gene mutations lead to i  nappropriate 
Hh signaling in BCC and medulloblastoma, a greater number 
of cancers are driven by Hh signaling through other mecha-
nisms, either in the bulk population of cells or specifically 
within the CSC population. We will briefly discuss the 
different mechanisms of Hh signaling, and for a complete 
review, the reader is referred to Reference 8.26 In both BCC 
and medulloblastoma, Hh pathway activation results from 
specific gene mutations and is independent of the presence 
of Hh ligand binding to Ptch. This mechanism of Hh activa-
tion, which is ligand-independent and driven by specific Hh 
gene mutations within the tumor cells, is termed Type I Hh 
signaling (Figure 2A).26 Hh inhibitors which are antagonists 
to Hh ligand will not be effective in overcoming this mecha-
nism of aberrant signaling because it occurs downstream 
and independent of ligand due to the mutation. The other 
mechanisms of Hh signaling observed in cancer rely upon 
Hh ligand initiation of the signaling, and vary by source and 
recipient cells of ligand secretion.
In Type II signaling, activation of the pathway is ligand-
dependent and autocrine, meaning it originates and is 
received by the tumor cells (or neighboring cells). Most data 
for Type II Hh signaling comes from in vitro studies in vari-
ous cancers including lung,48,49 prostate,50 glioblastoma,51,52 
gastrointestinal,11,53 breast,54 and leukemia.13,15 These studies 
observed Hh expression in tumor cells and growth inhibi-
tion with Hh blockade by cyclopamine in models absent of 
tumor stroma. This data supports the premise that Hh ligand 
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Figure 2 Modes of Hh pathway signaling. (A) Type I Hh signaling is activated by specific mutations within pathway genes within tumor cells, resulting in ligand-independent 
constitutive activation. (B) Type II Hh signaling results from autocrine signaling from tumor cell to tumor cell. (C) Type IIIa activation results from secretion of Hh ligand by 
tumor cells, resulting in pathway activation in surrounding tumor stroma. (D) Type IIIb Hh signaling results from Hh ligand secretion by tumor stroma, resulting in activation 
of the pathway within tumor cells themselves.
Abbreviation: Hh, Hedgehog.
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originates within the tumor cells and that pathway activation 
also occurs within tumor cells (either the same cells or neigh-
boring cells). Several authors remain unconvinced that Type II 
signaling actually exists in vivo because much of this data 
is based on studies with higher doses of cyclopamine which 
exhibit some non-specific cytotoxicity.25,26,46,55 However, in 
our group’s report of Hh signaling in acute lymphocytic 
leukemia (ALL), we demonstrated findings of increased Hh 
pathway expression in human ALL cell lines and clinical 
samples. Using a luceriferase reporter assay, we observed 
decreased Gli1 expression in ALL cell lines following 
treatment with 5E1, antagonist to Hh ligand, cyclopamine, 
or IPI-926 (Infinity Pharmaceuticals, Cambridge, MA), 
a semi-synthetic Smo inhibitor at doses which did not result 
in apoptosis or growth inhibition. Treatment with these Hh 
inhibitors resulted in decreased self-renewal when cells were 
treated alone without the presence of stromal cells both in 
in vitro clonogenic assays, as well as in serial transplantation 
models in mice. Although there is likely a contributory effect 
of stromally-mediated Hh signaling in ALL, we believe that 
our data also supports a role for autocrine, Type II Hh sig-
naling in ALL.15 Tumors characterized by Type II signaling 
may be susceptible to Hh inhibition at either the level of Hh 
ligand binding or further downstream.
A growing body of data confirms the importance of Type 
III Hh signaling which is ligand dependent and paracrine; 
that is, ligand is secreted by one type of cell (either tumor or 
stroma) and Hh pathway activation occurs in another (tumor 
or stroma). Ligand secretion by tumor cells resulting in Hh 
signaling in supportive stromal cells is termed Type IIIa sig-
naling, whereas ligand secretion by stromal cells resulting in 
Hh signaling in the tumor cells is termed reverse paracrine 
signaling or Type IIIb. Tumor types in which paracrine sig-
naling has been described include prostate,9 pancreas, and 
metastatic colon.25 Human prostate cancer cell lines showed 
enhanced growth in vivo with addition of Hh ligand while no 
differences were seen when cells were grown alone in vitro 
in absence of stroma, suggesting a role for stromally medi-
ated Hh signaling in promoting tumor growth. RT-PCR and 
in situ hybridization confirmed that increased tumor ligand 
expression correlated with increased mouse Gli1, Gli2, and 
Ptch1 from stromal cells.9 Yauch et al demonstrated similar 
findings of increased mouse Gli1 expression in response to 
human Hh ligand expression in pancreatic cancer and meta-
static colon cancer in xenografts from human cell lines and 
primary tumors.25 Importantly, these findings from mouse 
models were also seen upon examination of human clinical 
samples comprised of tumor cells and infiltrating stromal 
cells in   prostate, pancreatic, and metastatic colon cancer.9,56,57 
Type IIIb signaling has only been described in B-cell 
malignancies, including leukemia, MM, and non-Hodgkin’s 
  lymphoma.16 Hh ligands secreted by supportive stroma in 
lymph nodes, spleen, and bone marrow activated Hh signaling 
in tumor cells. Hh inhibition resulted in increased apoptosis 
associated with down regulated Bcl2 expression.
Hh inhibition as a CSC-targeted strategy
CSC theory states that tumors are comprised of two distinct 
populations of cells: a majority population of differentiated 
tumor cells which phenotypically characterize the disease; 
and a second population of rare, CSC or tumor-initiating 
cells, with properties of self-renewal and differentiation, 
responsible for disease maintenance and relapse.58,59 CSC 
theory attempts to explain the common clinical scenario 
of complete response to initial chemotherapy followed by 
relapsed disease propagated by a small population of residual 
cancer cells which were undetectable following initial 
therapy. For many cancers, conventional chemotherapy is 
effective against the bulk, differentiated tumor cells. Novel 
strategies targeting the residual CSCs responsible for disease 
recurrence are needed to prolong remissions, eradicate the 
tumor-initiating cells, and result in long-term cure. Hh sig-
naling has been identified as a potential CSC-specific target 
in various cancers.6,13,15,20,51,60–77
Techniques used to isolate and characterize CSC in vitro 
include aldehyde dehydrogenase expression, phenotypic 
markers, side population by Hoechst dye exclusion, and 
colony-forming assays. To date, the “gold standard” for 
CSC identification has been the ability of this rare popula-
tion of cells to regenerate tumor consisting of both pheno-
typic   populations, differentiated cells, and CSC in animal 
models.78 A detailed discussion of the in vitro and in vivo 
methods used to characterize CSC in various tumor types 
is beyond the scope of this review. The reader is referred 
to Reference 78 for further details of these techniques, as 
well to the publications cited below concerning Hh signal-
ing and CSC. CSC theory remains controversial due to the 
varying techniques for identification and the discrepancies 
in CSC numbers identified in primary samples and required 
to recreate tumors in mice by different researchers with 
varying techniques. Also, the inherent heterogeneity among 
different tumor types as well as within specific cancer types 
themselves. Regardless of the exact criteria for identifying 
CSC or properties of “stem-ness” or whether the CSC is a 
primitive progenitor or a de-differentiated cell, the clinical 
observation holds that rare populations of cancer cells persist 
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following initial therapy and cause disease recurrence, and 
novel strategies to target these resistant, persistent cells are 
needed. In fact, CSC from different cancers may share similar 
targets, even more so than the CSC and differentiated cell 
of the same cancer type. Hh signaling has been implicated 
in the bulk, differentiated cell populations of many human 
cancers, and here we review the preclinical evidence for Hh 
signaling in the CSC or self-renewing cells.
Our group demonstrated a role for Hh signaling in the 
self-renewing cells of MM and ALL. Flow cytometric 
analysis of MM cell lines following treatment with the Smo 
inhibitor cyclopamine resulted in decreases in the CD138-
negative cell fraction (the CSC population) as well as in side 
population (SP) cells. To assess the effects of Hh inhibition 
on self-renewal potential, an in vitro clonogenic assay was 
performed. In this assay, cells were treated with an anti-Shh 
antibody 5E1 to block ligand-dependent Hh signaling or the 
Smo inhibitor cyclopamine and then assayed for the ability 
to form tumor colonies in semi-solid media. Compared to a 
vehicle control, both 5E1 or cyclopamine significantly inhib-
ited colony-formation by MM cell lines and primarily clinical 
samples.20 Furthermore, this inhibitory effect was maintained 
during serial replating indicative of self-renewal potential. 
Similarly, in ALL, treatment of human ALL cell lines 
with the Smo inhibitors cyclopamine or IPI-926 resulted in 
decreased ALDH+ cells, decreased in vitro colony-formation, 
and decreased serial transplantation in mice, all reflective 
of effects on the self-renewing cell population.15 In chronic 
myeloid leukemia (CML) mouse models, Smo -/- mice had 
longer latency to develop CML when mouse bone marrow 
transduced with BCR-ABL was transplanted. A decrease in the 
number of phenotypically primitive cells (Lin- Sca-1- c-Kit+), 
a   surrogate for CSC, was also observed in the Smo -/- mice as 
compared to Smo +/+ mice.67 Similarly, Dierks et al transduced 
Smo -/- fetal liver cells with BCR-ABL and observed more 
rapid development of CML in transplanted mice. Secondary 
recipients of Smo -/- cells had no development of CML at 9+ 
months of observation. CML stem cells were isolated by flow 
cytometry and treated with the Smo inhibitor cyclopamine or 
Hh ligand blocking antibody 5E1. Decreased colony-formation 
in vitro was observed with both treatments, demonstrating 
a role for ligand-dependent Hh signaling in mediating self-
renewal in CML. Mice transplanted with BCR-ABL infected 
hematopoietic stem cells were treated with cyclopamine. All 
untreated animals rapidly developed CML and died within 
4 weeks, but cyclopamine-treated mice had a 60% survival 
at 7 weeks. In addition, CML from cyclopamine treated mice 
was unable to be serially transplanted, consistent with an 
observed decrease in the number of CML stem cells persisting 
after treatment.13
In glioblastoma multiforme, elevated Gli1 expression was 
seen in five of 19 primary samples and four of seven cell lines 
tested. Treatment with cyclopamine depleted the putative 
CSC population as identified by increased ALDH expression 
and SP. In vitro, glioblastoma multiforme neurospheres were 
unable to produce new neurospheres after exposure to cyclo-
pamine, and in vivo injection of cyclopamine treated glioblas-
toma multiforme cells did not result in tumor formation versus 
untreated cells, demonstrating that Hh inhibition with cyclo-
pamine eliminated the self-renewal capacity of these cells.52 
Tanaka et al demonstrated in human breast cancer cells that 
the CSC population, marked by either markers CD44+ CD24-/
low or SP had increased Hh expression and that proliferation 
was limited following treatment with siRNA against Gli1.79 
Similarly, Liu and colleagues isolated human breast tumor 
CSC by flow sorting for cells with markers CD44+ CD24-/low 
Lin-. Cyclopamine or siRNA against Gli1 or Gli2 inhibited 
Hh signaling, resulting in diminished self-renewal capacity, 
mediated by BMI-1, a known regulator of normal stem cell 
self-renewal.65 Tian et al looked at the effects of Hh inhibi-
tion with the synthetic Smo inhibitor GDC-0449 (Genentech, 
South San Francisco, CA; Curis, Lexington, MA; Roche, 
Basel, Switzerland) in lung cancer cell lines and used SP tech-
nique to isolate and enrich for CSC. They observed expres-
sion of Smo in the SP fraction, clonogenicity restricted to the 
SP fraction, and that treatment with GDC-0449 reduced the 
number of SP cells.73 Pancreatic CSCs as characterized by 
ALDH expression were preferentially reduced in number 
as compared to differentiated tumor cells when treated with 
cyclopamine.62 Similarly, Singh et al showed that Hh inhibition 
with GDC-0449 resulted in increased apoptosis of pancreatic 
cell line CSC as well as decreased transcription of Hh target 
genes.70 Other groups have described Hh signaling in the CSC 
of cancers of the prostate,60 stomach,71 colon,63 and ovary.80
Targeting Hh signaling in cancer
The identification of a naturally-occurring Hh pathway 
antagonist, cyclopamine, led to the subsequent development 
of synthetic and semi-synthetic derivatives of cyclopamine 
with increased potency and bioavailability. In addition, 
a commonly used anti-fungal agent, itraconazole, has also 
been found to have Hh inhibitory activity. These agents are 
now moving from the laboratory into clinical trials. Similar to 
challenges encountered in translating other targeted therapies, 
questions remain including the optimal way to integrate them 
into regimens of conventional chemotherapy. In addition, 
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our growing understanding of mechanisms of Hh signaling 
in different malignancies raises the issue of whether there 
should be different approaches to using these agents which 
vary by the mechanism of Hh signaling in each disease. 
Currently, all of the Hh inhibitors in clinical development are 
at the level of Smo, but other agents with distinct mechanisms 
of action have been identified and it is possible that these may 
be more or less effective depending on the mode of signaling. 
Below, we will discuss cyclopamine, itraconazole, and Smo 
inhibitors in clinical trials.
Cyclopamine
In the 1960s, teratogenic effects of ingestion of the corn lily 
Veratrum californicum were observed, resulting in one-eyed 
offspring (cyclopia) in lambs.81 It was subsequently discovered 
that the active agent, cyclopamine, exerted its effects through 
Hh pathway inhibition,82 specifically acting at the level of 
Smo.83 Cyclopamine displayed anti-tumor activity in vitro and 
in vivo, but poor oral bioavailability and acid sensitivity has 
prevented further clinical development. One clinical report of 
four patients with BCC, one of whom had Gorlin syndrome, 
described dramatic, rapid clinical regression of the lesions in 
response to topical cyclopamine application versus placebo. 
In addition, histological and immunohistochemical analysis 
showed apoptosis and increased markers of differentiation 
in response to Hh inhibition.84 Although no longer in clinical 
development due to increased potency and bioavailability of 
cyclopamine derivatives, cyclopamine remains an important 
agent in preclinical models of Hh inhibition.
Itraconazole
Interestingly, the anti-fungal agent itraconazole was found 
to have Hh inhibitory properties on a drug screen of known   
compounds. Kim et al showed that commonly used doses of 
itraconazole suppressed Hh pathway activity and inhibited 
growth of medulloblastoma in vivo. It appears to act on 
Smo, as does cyclopamine and its synthetic derivatives, but 
its mechanism of Smo antagonism is distinct from that of 
cyclopamine and appears to limit the ciliary accumulation 
of Smo.85 Itraconazole is currently in studies of patients with 
BCC, metastatic prostate cancer, and recurrent non-small cell 
lung cancer (see Table 1).
Synthetic and semi-synthetic cyclopamine 
derivatives
All of the Hh inhibitors in clinical trials currently act at the 
level of Smo (see Table 1 for a list of currently open clinical 
trials and Table 2 for a summary of findings of Smo inhibitors 
in clinical trials). Due to the decreased oral bioavailability 
and acid sensitivity of cyclopamine, semi-synthetic and 
synthetic derivatives have been developed. These derivatives 
appear to have increased potency and all are oral agents. Smo 
inhibitors currently under investigation appear to inhibit Smo 
through binding at the same portion of the transmembrane 
segment 6.86,87 Here, we will review the published or presented 
data regarding Smo inhibitors in clinical trials for cancer.
vismodegib
Early results from patients with medulloblastoma and BCC 
on the initial Phase I study of GDC-0449 were published in 
the New England Journal of Medicine in 2009 demonstrat-
ing a role for Smo inhibitors in cancers known to be driven 
by Hh pathway mutations.88,89 In the first report, one patient 
with heavily pre-treated medulloblastoma had clinical and 
radiographic regression of widespread systemic metastases 
on vismodegib. These results were short-lived, however, with 
Table 1 Smoothened inhibitors currently in clinical trials for cancer
Drug Sponsor Indications Phases
GDC-0449 Genentech, Curis,  
Roche
Advanced solid tumors, BCC, breast, chondrosarcoma, colorectal, gastric,  
Glioblastoma multiforme, medulloblastoma, multiple myeloma, ovarian,  
Pancreatic, prostate sarcoma, small cell lung
Phase II
LDE-225 Novartis Advanced solid tumors, BCC, chronic myeloid leukemia, pancreatic Phase I, II
BMS-833923 
(XL139)
Bristol-Myers Squibb,  
Exelixis
Advanced solid tumors, BCC, chronic myeloid leukemia, esophageal,  
gastric, multiple myeloma, small cell lung
Phase I, II
IPI-926 Infinity Advanced solid tumors, chondrosarcoma, head and neck, myelofibrosis,  
pancreatic
Phase I, II
PF-04449913 Pfizer Advanced solid tumors, hematologic malignancies Phase I
LEQ-506 Novartis Advanced solid tumors Phase I
TAK-441 Millenium Advanced solid tumors Phase I
Itraconazole BCC, metastatic prostate cancer, 
non-small cell lung cancer
Phase II
Note: As listed on clinicaltrials.gov on November 9, 2011.
Abbreviation: BCC, basal cell carcinoma.
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measurable increases in tumor size at 3 months of therapy and 
subsequent identification of a single amino acid substitution 
conferring resistance.89 A recent update of the entire Phase I 
cohort demonstrated that patients with BCC on vismodegib 
had a response rate of 58%. Twelve of 33 advanced BCC 
subjects had been on therapy from 8.5 months to 26.5 months, 
with median duration of response of 12.8 months (as of 
  January 2010, with several patients remaining on therapy and 
with continued response).90 Responses were only observed in 
the patients with medulloblastoma or BCC. At the American 
Society of Clinical Oncology (ASCO) Annual Meeting in 
2010, preliminary data was presented from eleven patients 
enrolled in a Phase I study of vismodegib in medulloblastoma 
coordinated through the Pediatric Brain Tumor Consortium. 
The limited data presented suggested that the drug was 
well-tolerated as a single agent in patients ranging from age 
4–20 years. Magnetic resonance imaging scans of the knees 
will monitor for changes in bone development, as this was 
a significant side effect observed in mouse studies with Hh 
inhibition.91
More recently, encouraging Phase II results with vismo-
degib in 99 patients with locally advanced or metastatic BCC 
were presented during the European Multidisciplinary Cancer 
Congress in 2011. In patients with metastatic disease, disease 
stabilization occurred in 63% with an overall response rate of 
30%. In locally advanced BCC, the overall response rate was 
43% with stable disease in 40% of patients. Median duration 
of progression-free survival was 9.5 months.92 The plenary 
session at the American Association for Cancer Research 
Annual Meeting in 2011 featured results from 36 patients 
on a Phase II study of vismodegib in patients with Gorlin 
Syndrome/Basal Cell Nevus Syndrome. This randomized, 
double-blind, placebo-controlled trial was designed to evaluate 
the efficacy of vismodegib in preventing the development of 
new BCC. The data safety monitoring board discontinued the 
placebo arm due to statistically significant differences in the 
number of new BCC (0.07 new BCC/month in treated patients 
vs 1.74 new BCC/month for those on placebo) and the change 
in size of existing BCC (decrease of 24 cm in vismodegib arm 
vs -3 cm in placebo arm).93 The 2011 ASCO Annual Meet-
ing featured two reports on vismodegib in combination with 
chemotherapy. A Phase I trial examined the combination of 
vismodegib with erlotinib and gemcitabine for unresectable 
pancreatic cancer. Observed dose-limiting toxicities of the 
combination included rash, nausea, infection, visual dis-
turbances, and thrombocytopenia. Transient responses with 
stable disease were seen in two dose cohorts, and a dose was 
determined for Phase II testing.94 An NCI-sponsored, random-
ized, double-blind placebo-controlled trial of chemotherapy 
with 5-fluorouracil and oxaliplatin (FOLFOX) with or without 
vismodegib in previously untreated patients with advanced 
gastric or gastroesophageal junction cancer was reviewed 
at the Trials in Progress poster session at the meeting. The 
study plans to enroll 116 patients in order to detect a 69% 
increase in progression-free survival. Laboratory correlative 
studies to look at effects on the tumor microenvironment are 
also planned.95
Across these early studies, there were no dose-limiting 
toxicities, and common side effects were mild and included 
muscle spasms, dysgeusia (taste alteration), fatigue, alope-
cia, and nausea. Grade 3 adverse events included reversible 
hyponatremia, abdominal pain, fatigue, and muscle cramps. 
Mild to moderate side effects included dysgeusia, muscle 
cramps, and weight loss, with two grade 3–4 adverse events 
Table 2 Summary of clinical findings from Phase I trials of Smoothened inhibitors in cancer
Parameter GDC-0449 (vismodegib) 
Genentech
IPI-926 
Infinity
LDE225 
Novartis
BMS-833923 (XL139) 
BMS/Exelexis
PF-0449913 
Pfizer
N (Phase I) 68 104+ (ongoing) 35+ (ongoing) 27 39+ (ongoing)
Daily doses  
explored (mg)
150–270–540 20–210 mg 100–200–400– 
800–1500
30–60–120–240–360–540 5–10–20–40–80–120–
180–270
GLI1 inhibition Yes Yes Yes Yes
Single dose t½ .7d ∼4d (1–10)? ∼7d? 17–35 hours
MTD defined? No (PK futility) No No Yes No
Grade 3 toxicities ↓ Na, fatigue ↑ LFTs, fatigue Asthenia ↓ phos, ↑ lipase Hypoxia, pleural  
effusions, 
hemorrhagic  
gastritis
Most common  
toxicities
Muscle spasms 
Dysgeusia 
Fatigue
Nausea, fatigue Nausea 
Muscle spasms 
Fatigue
Muscle spasms 
Dysgeusia
Dysgeusia 
Arthralgias 
Alopecia 
Nausea 
vomiting
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in the treatment arm (muscle cramps and suicide attempt). 
In the trial of vismodegib in patients with basal cell nevus 
syndrome, the drug was discontinued in 20% of patients due 
to adverse effects.92 Therefore, it appears that vismodegib is 
well tolerated.
IPI-926
IPI-926 (Infinity Pharmaceuticals, Cambridge, MA) is the 
only Smo inhibitor in development which is a semi-synthetic 
derivative of cyclopamine. Early phase clinical trial results 
were presented at the ASCO Annual Meeting in 2011. In the 
Phase I study of patients with locally advanced or metastatic 
solid tumors, partial responses were seen in patients with 
BCC, and several patients continued on therapy for more 
than 1 year.96 Preliminary findings from a Phase Ib/II study 
of IPI-926 in combination with gemcitabine in patients with 
untreated metastatic pancreatic cancer were also   presented. 
Median progression free survival was approximately 
5.5 months with five of 16 patients demonstrating a partial 
response to the combination.97 In both studies, the drug was 
well-tolerated with mild effects of nausea, fatigue, muscle 
spasms, and dysgeusia observed. There was also asymptom-
atic and reversible elevation of liver function tests.
LDE225
Two recent reports comment on the clinical experience with 
LDE225 (Novartis, Basel, Switzerland). Preliminary findings 
from a Phase I dose escalation study of LDE225 were reported 
at the ASCO Annual Meeting in 2010. One patient with 
medulloblastoma maintained a partial response for 4 months 
and five additional patients with various malignancies includ-
ing lung cancer and BCC have tolerated therapy for more 
than 4 months.98 A topical formulation of LDE225 was also 
recently tested in patients with Gorlin syndrome and BCC. 
In this double-blind, randomized, vehicle-controlled intra-
individual study, 27 BCC in eight patients were treated with 
LDE225 cream or vehicle twice daily for 4 weeks. In twelve of 
13 BCC, there were three complete responses and nine partial 
responses compared to only one partial response in 14 vehicle 
treated BCC.99 Similar to other Smo inhibitors, the oral drug 
was well-tolerated with side effects of fatigue, nausea, muscle 
cramps, and dysgeusia being most common. The topical 
formulation was well-tolerated with no skin irritation.
BMS-833923 (XL139)
BMS-833923 (XL139) (Bristol Myers Squibb, New York, 
NY; Exelixis, South San Francisco, CA) is also being studied 
in early phase trials as a single agent in advanced and metastatic 
solid tumors. There are   ongoing clinical trials looking at this 
drug in combination with standard chemotherapy in MM, 
gastric and esophageal cancers, and small cell lung cancer. 
Data was presented at the American Association for Cancer 
Research-National Cancer Institute-European Organization 
for Research and Treatment of Cancer Annual Meeting in 
2009. One patient with medulloblastoma continues on study 
for more than 10 months with stable disease. A second subject 
with Gorlin syndrome had a partial response to therapy which 
was ongoing at the time of the report.100 At the 2011 American 
Society of Hematology meeting, Huff et al presented Phase 
I data on BMS-833293 in patients with MM. BMS-833923 
was given either as monotherapy, or in combination with 
lenalidomide plus dexamethasone, or with bortezomib in 
patients with relapsed or refractory MM. No clinical response 
data had been analyzed to date.101 In both trials, the drug was 
well-tolerated with the most common side effects being dys-
geusia, muscle spasms, and nausea. There was one episode 
of grade 2 lipase elevation and pancreatitis.
PF-04449913
Preliminary data was presented in abstract form with 
PF-04449913 (Pfizer, Manhattan, NY) at the 2011   American 
Society of Hematology Annual Meeting. The drug was 
administered as a single agent in escalating doses in a Phase 
Ia study of 32 patients with various hematologic malignancies 
including acute myeloid leukemia, CML in lymphoid blast 
crisis, myelodysplastic syndrome, myelofibrosis, and chronic 
myelomonocytic leukemia. Some evidence of response was 
seen in all disease subsets, and one patient with acute myeloid 
leukemia evolved from chronic myelomonocytic leukemia 
achieved a complete remission with incomplete blood count 
recovery. Five patients with acute myeloid leukemia had 
significant reduction in circulating blast counts, and one 
patient with T315I mutation CML in lymphoid blast crisis 
achieved a major cytogenetic response with loss of the T315I 
mutation. Other patients had hematologic improvement or 
disease stabilization. The drug was relatively well-tolerated 
with the most common side effects being dysgeusia, alopecia, 
nausea, and arthralgias.102 An expanded multicenter Phase 
Ib/II study is planned in combination with chemotherapy in 
hematologic malignancies as well.
Discussion
Preclinical in vitro and in vivo data with Hh signaling demon-
strate a role for the pathway in the pathogenesis, self-renewal, 
and chemotherapy resistance in a variety of human cancers. 
Years of laboratory investigations have led to Phase I trials 
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of several Smo inhibitors which appear to be relatively well-
tolerated either as single agents or in combination regimens 
with conventional chemotherapy. Modest side effects include 
nausea, dysgeusia, muscle cramps, and fatigue, with rare 
grade 3 adverse events observed. It is unclear, however, what 
side effects may occur in children, as permanent defects in 
bone growth have been seen in mouse models of Hh inhibi-
tors91 which may complicate their clinical development for 
pediatric tumors such as medulloblastoma. The known 
teratogenic effects of cyclopamine caution for the need to 
prevent pregnancy in treated subjects.   Encouraging prelimi-
nary results have led to ongoing clinical trials in adults in 
hematologic malignancies, pancreatic cancer, glioblastoma, 
gastrointestinal tumors, lung cancer, and other advanced solid 
tumors. These early trials may suggest how to incorporate 
Smo inhibitors into treatment regimens with conventional 
chemotherapy. Interestingly, many of these trials incorporate 
prolonged post-chemotherapy maintenance therapy with the 
Smo inhibitor, reflecting an understanding of the potential 
role of Hh signaling in maintaining the CSC population which 
persists after initial therapy.
Despite early enthusiasm and preclinical successes, chal-
lenges remain in the development of Smo inhibitors. Drug 
resistance is an important concern. Preclinical models sug-
gest several potential mechanisms of resistance, but the most 
compelling data comes from one clinical example, the first 
patient treated with the Smo inhibitor vismodegib for refrac-
tory medulloblastoma. Despite an initial dramatic response to 
therapy, resistant disease emerged after 3 months with relapse 
at multiple sites.89 Tumor biopsies taken both before and after 
vismodegib provided important insights into the mechanisms 
of resistance to Smo inhibitors. Yauch and colleagues were 
able to identify a single amino acid substitution in a conserved 
aspartate acid residue of Smo. This mutation retained Smo 
activity but interfered with vismodegib binding, preventing 
the drug effect. Whether this mutation arose in the setting 
of vismodegib therapy or was present at levels too low to 
be detected pre-treatment remains unclear. In mouse models 
of medulloblastoma, the same mutation was identified in a 
tumor resistant to vismodegib as well.103 Similar to the devel-
opment of BCR-ABL tyrosine kinase inhibitors which retain 
activity against mutations conferring resistance to imatinib, 
studies are underway to develop second-generation Smo 
inhibitors which remain effective in the face of known Smo 
mutations conferring drug resistance.104 Other mechanisms 
of resistance that have been identified in preclinical models 
include amplification of Hh signaling molecules downstream 
of Smo (cf, Gli2),104 amplification of Hh target genes,105 and 
upregulation of signaling pathways which interact with Hh, 
such as PI3K.41 In addition, aberrant Hh signaling may result 
from pathway activation downstream of Smo. Hh inhibi-
tors which act at the level of the Gli transcription factors 
are also under investigation in the laboratory,106 and may 
prove effective in the setting of Smo inhibitor resistance or 
in combination. For example, arsenic trioxide, used in the 
treatment of acute promyelocytic leukemia, has been shown 
to inhibit Gli proteins.107,108
Preclinical testing of Smo inhibitors has identified tumor 
types which appear dependent on Hh signaling for their 
growth, self-renewal, and chemotherapy resistance. Hh 
signaling does not appear consistent throughout any tumor 
type, including those with specific activating mutations such 
as BCC and medulloblastoma, in which a majority of tumors 
may be dependent on the pathway. At this time, testing to 
know which particular patients and tumors are dependent 
on Hh signaling is not available. Efficacy results from early 
phase trials of these agents should be interpreted cautiously, 
as the effects may be more pronounced in only specific sub-
sets of patients, and we are currently unable to prospectively 
identify them. The potential to profile an individual’s own 
tumor for dependence on Hh or other signaling pathways 
would better direct patients into clinical trials and suggest 
potential synergistic combinations of inhibitors. However, 
current techniques do not permit this level of personalized 
medicine.
The development of Smo inhibitors represents an exciting 
advance in cancer therapy. Hh signaling is a cancer-specific 
target in adults, and likely a CSC-specific target in several 
diseases, with the potential to have efficacy as single agents 
and in order to sensitize tumors to chemotherapy. As these 
clinical trials provide tumor samples and outcomes suggest-
ing which patients may benefit, additional questions will 
need to be answered through laboratory correlative studies 
to better identify which patients and tumor types are most 
likely to be responsive to these interventions. Clinical trials 
of CSC-targeted therapies such as Hh inhibition may not 
produce early measurable clinical responses, but may instead 
prolong survival as the CSC are extinguished over time. 
In cancers where the role of Hh signaling may be due to a 
tumor-stromal interaction, Hh inhibition alone may result in 
a cytostatic effect with no measurable benefit radiographi-
cally but an improvement in survival. These factors must be 
considered as clinical trials incorporate Smo inhibitors with 
traditional chemotherapy, and overall survival represents 
the ideal endpoint to assess efficacy of a treatment such as 
this with potential CSC- or stroma-specific effects. A better 
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understanding of the role of Hh signaling in the response of 
tumors to traditional therapy, as well as the interactions of 
the Hh pathway with other signaling pathways, may suggest 
combinations of Smo inhibitors with other pathway inhibitors 
for further study.
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